PO12 | IMPACT OF INHERITED THROMBOPHILIA ON CANCER-ASSOCIATED THROMBOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
E. Campello1, G. Furlan1, A. Boccatonda2, A. Napolitano1, C. Simion1, P. Simioni1 | 1Internal Medicine 1 and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padova, Italy; 2Diagnostic and Therapeutic Interventional Ultrasound Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, Bologna, Italy
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Introduction. Cancer-associated thrombosis (CAT) is a frequent and clinically relevant complication in patients with malignancy. While inherited thrombophilia is a well-established risk factor for venous thromboembolism in the general population, its contribution to CAT remains uncertain, and routine thrombophilia testing is not recommended in current guidelines.
Aim. The aim is to evaluate the association between inherited thrombophilia, specifically factor V Leiden and the prothrombin G20210A mutation, and the risk of CAT.
Materials and Methods. We conducted a systematic review and meta-analysis in accordance with PRISMA 2020 guidelines. Observational studies enrolling adult cancer patients with and without VTE were included. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using random-effects Mantel–Haenszel models. Heterogeneity was assessed using the I² statistic. Risk of bias was evaluated using the Newcastle–Ottawa Scale, and certainty of evidence was assessed with the GRADE approach.
Results. Eight studies evaluating factor V Leiden and six studies evaluating the prothrombin G20210A mutation met the inclusion criteria. As shown in Figure 1, factor V Leiden was significantly associated with an increased risk of cancer-associated thrombosis (pooled OR 2.75, 95% CI 1.34–5.64; p = 0.006), with moderate heterogeneity (I² = 64%) (A). The prothrombin G20210A mutation was also associated with CAT (pooled OR 2.17, 95% CI 1.06–4.45; p = 0.03), with no observed heterogeneity (I² = 0%) (B). Sensitivity analysis excluding studies primarily focused on catheter-related thrombosis confirmed the robustness of the association between factor V Leiden and CAT (pooled OR 2.52, 95% CI 1.17–5.45; p = 0.02; I² = 67%) (Figure 1,C). Severe inherited thrombophilia could not be quantitatively analyzed because it was reported in only one eligible study. According to GRADE, the certainty of evidence was rated as moderate for factor V Leiden and low for the prothrombin G20210A mutation.
Conclusions. Inherited thrombophilia, particularly factor V Leiden, is associated with an increased risk of CAT. These findings support a role for genetic predisposition as a risk modifier in CAT and may contribute to refined, individualized risk stratification strategies in selected cancer populations.
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Most read articles by the same author(s)
- Società Italiana di Emostasi e Trombosi, OC04 | DIRECT ORAL ANTICOAGULANTS PROVIDE EFFECTIVE THROMBOPROPHYLAXIS IN NEWLY DIAGNOSED MYELOMA: REAL WORLD FINDINGS FROM THE ATOMM STUDY , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, OC09 | BLEEDING RISK ASSOCIATED WITH FACTOR XI MONOCLONAL ANTIBODIES IN COMBINATION WITH ASPIRIN IN HEALTHY VOLUNTEERS AND ORTHOPEDIC SURGERY PATIENTS: ANALYSIS FROM RECENT PHASE 1 AND PHASE 2 STUDIES , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO67 | TARGETED THERAPIES FOR CANCER AND THE RISK OF ARTERIAL AND VENOUS THROMBOEMBOLISM , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO04 | FIBRIN CLOT SHIELDS PROMOTE CLONAL SELECTION IN CANCER CELLS: PROCOAGULANT ACTIVITY AND SURVIVAL OF CLOT-EMBEDDED CELLS. A NOVEL TUMOR MICROENVIRONMENT MODEL , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, OC10 | FROM DESIGN TO CLINICAL PHASE 3 IN ONCOLOGY: CD13-TARGETED TISSUE FACTOR AND TUMOR INFARCTION , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO29 | CANADIAN INSIGHTS INTO THE MANAGEMENT OF BREAKTHROUGH THROMBOSIS , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO45 | KHORANA RISK SCORE AND GENOMIC PROFILING FOR PREDICTION OF VENOUS THROMBOEMBOLISM IN OVARIAN CANCER , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO03 | HEPATIC FIBROSIS–DRIVEN TISSUE FACTOR EXPRESSION BY MALIGNANT CHOLANGIOCYTES IS ASSOCIATED WITH CANCER-ASSOCIATED THROMBOSIS AND POOR SURVIVAL IN INTRAHEPATIC CHOLANGIOCARCINOMA , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO61 | RISK FACTORS FOR INTRACRANIAL HEMORRHAGE: AN UMBRELLA REVIEW TO INFORM MACHINE LEARNING PREDICTION MODELS IN GLIOMA PATIENTS RECEIVING ANTICOAGULATION , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO11 | THROMBOEMBOLIC EVENTS DURING PERIOPERATIVE THERAPY FOR RESECTABLE AND BORDERLINE RESECTABLE PANCREATIC CANCER IN THE PREOPANC-2 TRIAL , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
